SCHEMBL1884547

SCHEMBL1884547

[CH2][C@H](CNC(=O)OCOC(=O)C(C)(C)C)c1ccc(Cl)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 5/20 0.36
NPC1 O15118 2/20 0.36
CYP1A2 P05177 2/20 0.36
KMT2A Q03164 2/20 0.36
RAB9A P51151 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ELANE P08246 1/20 0.35
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP3A4 P08684 2/20 0.35
ABCB11 O95342 1/20 0.35
TSHR P16473 1/20 0.35
HTR2A P28223 1/20 0.35
PMP22 Q01453 1/20 0.35
PPARA Q07869 1/20 0.35
PRKCA P17252 1/20 0.34
PRKCE Q02156 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1884816 1.00 MAPT (0.36) MAPTL3MBTL1NPC1CYP1A2KMT2A
SCHEMBL1885017 0.85 MAPT (0.40) MAPTL3MBTL1NPC1KMT2ARAB9A
SCHEMBL1884874 0.85 MAPT (0.40) MAPTL3MBTL1NPC1KMT2ARAB9A
SCHEMBL1888752 0.82 L3MBTL1 (0.41) MAPTL3MBTL1NPC1CYP1A2KMT2A
SCHEMBL1884157 0.82 L3MBTL1 (0.41) MAPTL3MBTL1NPC1CYP1A2KMT2A
SCHEMBL2231116 0.82 ATM (0.47) MAPTCYP1A2KMT2ACYP2C9CYP2C19
SCHEMBL1886106 0.81 MAPT (0.41) MAPTL3MBTL1NPC1CYP1A2KMT2A
SCHEMBL1890710 0.81 MAPT (0.41) MAPTL3MBTL1NPC1CYP1A2KMT2A
SCHEMBL27693091 0.80 GAA (0.47) MAPTGAASMN1; SMN2TSHRPPARA
SCHEMBL1884548 0.78 SMN1; SMN2 (0.37) L3MBTL1NPC1CYP1A2KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935686-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2011-05-03 US disclosed
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use XENOPORT, INC. (US) 2009-05-14 US disclosed
US-7494985-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2009-02-24 US disclosed
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use APEH, AASDHPPT, AGPS MAPT 4107/4885L3MBTL1 2410/4885NPC1 1799/4885
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use APEH, AASDHPPT, AGPS MAPT 4107/4885L3MBTL1 2410/4885NPC1 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.